Celldex Therapeutics Inc. (CLDX) Hits New 52-week Low During January 27 Session

Equities Staff |

Celldex Therapeutics Inc. (CLDX) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $10.00, Celldex Therapeutics Inc. dropped to $9.46 for a new 52-week low. By the closing bell, the company's stock was at $9.50 a share for a loss of 4.9%.

Falling to a new 52-week low is never fun for company's shareholder, but, depending on who you ask, it can be either a buy or a sell signal. Someone bearish on the stock might see it reaching its lowest price in a year as a sign of growing downward momentum and make sure they sell their shares. Bulls, though, are more likely to see a new 52-week low as the stock hitting its low point and anticipate a bounce in the share price.

However one plays it, it's often a critical moment for any stock and should be noted by investors.

Celldex Therapeutics Inc. saw 2.23 million shares of its stock trade hands, that's out of 98.65 million shares outstand. The stock has an average daily volume of 2.15 million shares. After hitting a new 52-week low, Celldex Therapeutics Inc. enters the new trading day with a market cap of 937.13 million, a 50-day SMA of $14.64 and a 200-day SMA of $19.04

For a complete fundamental analysis analysis of Celldex Therapeutics Inc., check out Equities.com’s Stock Valuation Analysis report for CLDX. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

Celldex Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the development, manufacturing and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.

Celldex Therapeutics Inc. has 161 employees, is led by CEO Anthony S. Marucci, and makes its home in Hampton, NJ.

Celldex Therapeutics Inc. is also a component of the Russell 2000 Index, which is generally viewed as the most reliable indicator of the health of the broader small-cap market. Using a rules-based methodology, it creates a simple, unbiased view of how America's stable of smaller publicly traded companies are performing in the stock markets.

The index consists of the 2,000 smallest companies of the 3,000 largest publicly-traded companies in the country as judged by market cap. It's constructed by Russell Investments, which also builds and maintains the Russell 3000 (an index consisting of all 3,000 biggest companies by market cap) and the large-cap Russell 1000 (which has the 1,000 largest companies from the Russell 3000).

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Breathtec BioMedical Inc.

Breathtec Biomedical Inc is a medical diagnostics company. It is engaged in developing & commercializing breath analysis devices for the early detection of infections & life threatening diseases including cancers,…

Private Markets

WayBetter

The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…

Cloudera

Cloudera offers enterprises a new data platform built on the Apache Hadoop open-source software package. Hadoop is a data-management platform that can consolidate data in a single repository for comprehensive…